Search

Cambrian Bioworks, a Bengaluru-based company, has raised $1.45 million in seed funding to develop advanced solutions for the next-generation sequencing and molecular diagnostic markets. The funding will be used to accelerate the development of Cambrian's automated molecular diagnostics platforms, expand the team, and support international expansion. The company aims to enable widespread access to automated devices for liquid biopsy testing and targeted sequencing. This funding follows the success of Cambrian's nucleic acid extraction platform, Manta. [Extracted from the article]

Shriram Properties, a real estate company in South India, has announced that ASK Property Fund has made an "early exit" from one of its projects in Bengaluru, resulting in a significant return on investment. The project, called Shriram Pristine Estate, involved a co-investment scheme with partners investing Rs 85 crore in 2022. ASK Property Fund realized a return of 20% IRR and an investment multiple of 1.24x in less than 18 months. In other news, Cambrian Bioworks has raised $1.45 million in seed funding to develop advanced solutions for the next-generation sequencing and molecular diagnostic markets in India. [Extracted from the article]

The article focuses on a new India-UK research project, Diagnostics for One Health and User-Driven Solutions for Antimicrobial Resistance (DOSA2), aiming to trial an easy-to-use test for urinary tract infections (UTI) to combat the global threat of antimicrobial resistance (AMR).

The article discusses the development of rapid molecular influenza diagnostic test by biotechnology company Mesa Biotech. The benefits of molecular-based testing such as accuracy, time management, and lower antibiotic resistance is also discussed. Comments by its chief executive Hong Cai on the importance of integrating technology for better results is presented.

The article offers information on the collaboration between Children's Hospital Orange County and Rady Children's Hospital San Diego in California to improve the molecular diagnosis of rare and common complex genetic diseases in children, and presents the views of hospitals' executives on it.

The article offers information on the diagnostics industry in San Diego, California. It mentions how SpectraScience Inc. markets their diagnostic tools and devices, and how it effects health services in the U.S. It also features how the partnership of Life Technologies Corp. and Quidel Corp. helps in providing molecular diagnostics to European market.

A calendar of business events in San Diego, California from October-November 2014 is presented which include the Recruit @ Rady Career & Internship Fair, the BIOCOM's Science of Molecular Diagnostics event, and the San Diego Venture Group's Life Science and Innovation event.

The article reports that the approval of an automated molecular diagnostic test by the U.S. Food and Drug Administration (FDA), wherein the automated molecular diagnostic test is used to detect influenza A, influenza B and respiratory syncytial virus.

The article focuses on a report by insurer UnitedHealth Group Inc., according to which, genetic tests will take over the U.S. annual market with its 25 billion dollar within a decade. It further informs that genetic exams pose a challenge to the consumers, doctors and the U.S. government in terms of monetary issues. It also states that UnitedHealth has spent 500 million dollar for genetic exams and molecular diagnostics targeting cancer and HIV in the year 2010.

An interview with Fred C. Tenover, senior director for scientific affairs at molecular diagnostic company Cepheid. Asked what did he plan to do once he decided he wanted to get a doctor of philosophy degree, he answered that he wanted to continue to conduct research in antibiotic resistance. He explained the progress of his career in science research such as working with the Centers for Disease Control and Prevention in the U.S. He considered drug-resistant bacteria to be a more serious threat that flu.

The article reports on the $10 million in financing received by High Throughput Genomics Inc. in Tucson, Arizona to expand research and product development in molecular diagnostics and proteomics for the pharmaceutical and life science industries. Merck Capital Ventures, Solstice Capital, and Valley Ventures were involved in the financing. Harry George, managing partner of Solstice will become chairman of High Throughput as part of the funding.

Focuses on challenges for scientists and companies, as they race to develop diagnostic tests to quickly determine whether a person has severe acute respiratory syndrome (SARS). Issue of whether the tests themselves are accurate; Why development of experimental tests has progressed slowly; Importance of an accurate test for public health; Test that was developed by the Centers for Disease Control and Prevention; Advantages of the technique of polymerase chain reaction (PCR); Highlights of the testing; Outlook.

Looks at the efforts of cancer researchers to identify molecular "fingerprints" in tumors to predict whether a cancer is likely to spread quickly and lead to early death. Perception that these findings could revolutionize how cancers are treated; Outlook for the use of molecular tumor signatures to predict which patients are most likely to respond to radiation or chemotherapy; Mention of a study in the "New England Journal of Medicine" which showed that a fingerprint derived from the activity of tumor genes can predict whether early-stage breast cancer is likely to metastasize.

Discusses the commercial medical laboratory industry in the United States. How field of genomics will affect development of molecular diagnostics; Information about and costs of gene-based tests; History of lab business; Consolidation in industry; Mention of finances of several lab companies, including Impath and Quest Diagnostics.